Skip to Content
You are currently on the new version of our website. Access the old version .
CancersCancers
  • Comment
  • Open Access

20 July 2021

4 Pages

Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176

,
and
1
Department of Medical and Thoracic Oncology, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Université de Paris, 75015 Paris, France
2
Centre d’Investifation Clinique (Epidémiologie Clinique) INSERM 1418, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, 75015 Paris, France
3
Medical Oncology Department, Hospital Clinic of Barcelona, 08036 Barcelona, Spain
4
Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, The August Pi i Sunyer Biomedical Research Institute IDIBAPS, 08036 Barcelona, Spain

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

We read, with great interest, the recently published article by Hopkins et al. [...]

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.